PATENT CLAIM ANALYSIS

Application Number: 16041167
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "208100"]

Abstract:
Methods for inducing safe and effective immune response against multiple clades of Human Immunodeficiency Virus (HIV) infection in human subjects are described. The methods involve heterologous vaccine combinations of adenovirus serotype 26 expression vectors expressing at least three mosaic HIV antigens with at least one isolated HIV gp140 protein.

Claim (Index 1):
A method of inducing a safe and effective immune response against multiple clades of human immunodeficiency virus (HIV) in a human subject in need thereof, comprising:\n (1) administering to the subject a priming composition comprising one or more Ad26 vectors together encoding at least three HIV antigenic polypeptides having the amino acid sequences of SEQ ID NO: 1, SEQ ID: NO 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, in a total dose of about 5\u00d710 9  to about 1\u00d710 11  viral particles (vp) of the Ad26 vectors; (2) administering to the subject, about 10-14 weeks after (1), the priming composition at a total dose of about 5\u00d710 9  to about 1\u00d710 11  vp of the Ad26 vectors; (3) administering to the subject, about 22-26 weeks after (1), a first boosting composition comprising at least one isolated HIV envelope glycoprotein having the amino acid sequence of SEQ ID NO: 5, an aluminum phosphate adjuvant and a pharmaceutically acceptable carrier, at a total dose of about 125 \u03bcg to 350 \u03bcg of the at least one isolated HIV envelope glycoprotein; (4) administering to the subject, together with (3), a second boosting composition comprising one or more Ad26 vectors together encoding the at least three HIV antigenic polypeptides and a pharmaceutically acceptable carrier, at a total dose of about 5\u00d710 9  to about 1\u00d710 11  vp of the Ad26 vectors; or administering to the subject, together with (3), a second alternative boosting composition comprising one or more MVA vectors together encoding the at least three HIV antigenic polypeptides, and a pharmaceutically acceptable carrier, at a total dose of about 10 7  to about 10 9  plaque-forming units (pfu) of the MVA vectors, wherein the safe and effective immune response comprises an antibody-dependent cellular phagocytosis (ADCP) response to isolated HIV envelope glycoproteins from clades B and C at a median response rate of at least 56%.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.12766
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15968834', '14863808', '15693650', '15380123', '13130018']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7128091279597105
- 35 USC 102 Novelty (BERT): 0.6155487974626495
- Combined Prediction Score: 0.7030830949100044
- Mean Citation Score: 472.678518
- Max Citation Score: 600.1256
- Similarity Product: 476.4199048922537

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test